Intensity Therapeutics has been recognised with GHP Magazine’s 2026 Healthcare & Pharmaceutical Award, receiving the Cancer Treatment Technology Innovator of the Year 2026 – USA distinction.
The recognition highlights the company’s work in developing proprietary cancer therapies using its non-covalent drug-conjugation technology designed to kill tumors and enhance immune system recognition of cancers.
Also read: Cleveland Clinic Abu Dhabi Performs First UAE–Pakistan Remote Robotic Kidney Telesurgery
The award comes as Intensity Therapeutics continues advancing its lead candidate, INT230-6, which has shown encouraging clinical outcomes in patients with advanced cancers, including sarcoma and breast cancer.
Lewis H. Bender, Co-Founder and CEO of Intensity Therapeutics, said “The recognition reflects the company’s commitment to advancing innovative cancer care and developing new approaches for immunotherapy-resistant malignancies.”
GHP Magazine recognised the company for its innovation in intratumoral injection drug delivery technology following an evaluation of its research, business performance, and potential impact on patient outcomes.
